Navigation Links
Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated

NEW YORK, May 29, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at ViroPharma Incorporated ("ViroPharma" or the "Company") (NASDAQ: VPHM).

(Logo: )

The investigation focuses on the Company's product Vancocin, which uses the Vancomycin antibiotic.  On December 14, 2011, the Company issued a press release stating that it believed that Vancocin would have three years of marketing exclusivity due to changes in its label, and that generic Vancomycin capsules would not be approved during that period.  Following this news, ViroPharma's stock price rose 17.9% to close at $27.80 per share on December 14, 2011.

However, on April 10, 2012, ViroPharma announced that the FDA had informed the Company that Vancocin's new label would not qualify the product for three additional years of exclusivity, and that the FDA had indicated it is approving three applications for generic Vancomycin capsules.  Following this news, the price of ViroPharma common stock dropped 22% to close at $22.44 per share on April 10, 2012. 

Request more information now by clicking here:

Take Action
If you purchased ViroPharma securities between December 14, 2011 and April 9, 2012 and would like to discuss your legal rights, visit You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to or  Faruqi & Faruqi, LLP also encourages anyone with information regarding ViroPharma's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential matter.

369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292 or (212) 983-9330


SOURCE Faruqi & Faruqi, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Faruqi & Faruqi, LLP Announces Investigation of ZELTIQ Aesthetics, Inc.
3. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
4. Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
5. Masimo to Present at William Blair & Company 32nd Annual Growth Stock Conference
6. Acacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)
7. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
8. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
9. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
10. Medical Device Developers - Network at MD&M East Next Week
11. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):